RT Journal Article
SR Electronic
T1 Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 889
OP 894
DO 10.15537/smj.2017.9.19349
VO 38
IS 9
A1 Ren, Hui
A1 Wang, Kai
A1 Yang, Hao
A1 Gao, Lingyun
YR 2017
UL http://smj.org.sa/content/38/9/889.abstract
AB Objectives: To analyze the efficacy and adverse events (AEs) of pirfenidone in idiopathic pulmonary fibrosis (IPF) trials.Methods: MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for studies published before June 2016. All studies of clinical trials with the key words IPF or idiopathic pulmonary fibrosis or lung fibrosis and pirfenidone or Esbriet were identified. Quality assessment and data extraction were conducted by 2 independent researchers. A meta-analysis of randomized controlled trials (RCTs) was performed, and relative risk (RR) and 95% confidence intervals (95% CIs) were calculated.Results: Five studies were included in this review, involving 1568 participants. The meta-analysis revealed that pirfenidone reduced the risk of decline in forced vital capacity (FVC)% ≥10% from baseline (relative risk: 0.62; 95% CI: 0.51-0.76, p<0.001). The pirfenidone group had a significantly higher rate of AEs compared with the placebo group. Pirfenidone did not reduce mortality from any cause significantly (odds ratio: 0.63; 95% CI: 0.36-1.09).Conclusions: This study showed that pirfenidone could reduce disease progression as assessed by the decline in FVC in IPF. Pirfenidone represents a suitable treatment option for patients with IPF.